In this issue of Blood, Liu et al show that response to thrombopoietin receptor agonist (TPO-RA) therapy in immune thrombocytopenia (ITP) is associated with restoration of monocyte Fcg receptor (FcgR) balance toward inhibitory FcgRIIb and with correction of the enhanced phagocytic capacity of macrophages. These data suggest that TPO-RA can increase platelet counts not only by increasing platelet production but also by lowering platelet destruction. 
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TP is an immune-mediated bleeding disorder resulting from reduced platelet production as well as increased platelet destruction due to antiplatelet autoantibodies binding to platelets and causing their premature destruction by Fc-mediated phagocytosis in the reticuloendothelial system. 2 In recent years, TPO-RAs have emerged as highly efficacious in the management of primary ITP and 2 drugs, romiplostim and eltrombopag, are approved for standard clinical use. Through activation of TPO-R on megakaryocytes, TPO-RAs stimulate platelet production. An increase in platelet counts is achieved in 60% to 80% of patients with chronic ITP who have been refractory to 1 or more lines of therapy. Along with their ability to directly stimulate thrombopoiesis, TPO-RAs have been shown to affect immunomodulation. In a mouse model of ITP, short-term TPO-RA treatment promoted the peripheral induction of regulatory T cells (Tregs) and suppressed T-cell responses to platelet autoantigens. 7 Furthermore, improved Treg activity and decreased effector T-helper cell function have been observed in TPO-RA-treated ITP patients. 8 In addition, regulatory B-cell (Breg) number and function were also corrected after TPO-RA treatment in ITP patients. 9 Taking into account the immunoregulatory actions of TPO-RAs and the important role of FcgRs in autoimmunity, Liu et al examined the effect of TPO-RAs on FcgR modulation and the platelet destruction process in ITP (see figure). . In addition to their direct effect on activating TPO-Rs on megakaryocytes that result in platelet production, TPO-RAs restore FcgR balance on monocytes/macrophages and downregulate the phagocytic capacity of macrophages, thus attenuating platelet destruction. The mechanism of action of how this occurs remains to be discovered. It may be that the increase in platelet mass following TPO-RA treatment results in elevated levels of circulating transforming growth factor-b1 (TGFb1) which, directly or indirectly through increasing Treg activity, restores FcgR balance and inhibits macrophage phagocytic activity.
inhibitory FcgRII expression on splenic macrophages, and these FcgR level changes correlated with increase in platelet counts. Furthermore, clearance of transfused platelets appeared slower in ITP mice treated with romiplostim. These exciting and novel data suggest that TPO-RAs may lower platelet destruction in addition to stimulating platelet production. Nevertheless, the study is still an association. Direct proof that TPO-RAs increase platelet counts or improve transfused platelet survival in ITP by modulating FcgRs will require future studies showing that TPO-RA effects on platelet counts in ITP FcgRII and/or FcgR chain knockout mice are abolished. Several recent studies have shown a sustained platelet response after TPO-RA discontinuation in a subset of ITP patients.
10
If the monocyte FcgR balance toward inhibitory FcgRIIb is maintained and the macrophage phagocytic activity remains low in patients who have sustained remission after TPO-RA discontinuation, but not in those who relapse, it would further support the aforementioned effects of TPO-RAs on FcgR modulation and inhibition of platelet destruction in ITP. Questions remain as to the mechanism of action of TPO-RA on monocyte/macrophage FcgR expression and function: does the burst in plasma TGFb1 following TPO-RA treatment 1, 8 directly affect and lower phagocytic activity of monocyte/macrophages? Or is the effect mediated through Tregs or Bregs which can regulate monocyte activity? Nonetheless, this research sheds new light on TPO-RA immunomodulation and helps to guide research to uncover a novel mechanism of action of TPO-RAs in ITP treatment. Such investigations will help determine whether the immunomodulatory effects of TPO-RAs are specific to the treatment of ITP immunopathology or whether they can be harnessed for treatment of other autoimmune diseases without causing thrombocytosis. Conflict-of-interest disclosure: The author declares no competing financial interests. n
